| Bioactivity | Carbosulfan inhibited relatively potently CYP3A4 and moderately CYP1A1/2 and CYP2C19 in pooled HLM (human livers). Carbosulfan activation is predominantly catalyzed in humans by CYP3A4. | ||||||||||||
| Name | Carbosulfan | ||||||||||||
| CAS | 55285-14-8 | ||||||||||||
| Formula | C20H32N2O3S | ||||||||||||
| Molar Mass | 380.54 | ||||||||||||
| Appearance | Liquid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Abass K, et al. Metabolism of carbosulfan II. Human interindividual variability in its in vitro hepatic biotransformation and the identification of the cytochrome P450 isoforms involved. Chem Biol Interact. 2010 May 14;185(3):163-173. |
Carbosulfan
CAS: 55285-14-8 F: C20H32N2O3S W: 380.54
Carbosulfan inhibited relatively potently CYP3A4 and moderately CYP1A1/2 and CYP2C19 in pooled HLM (human livers). Carbo
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.